Treprostinil in advanced experimental pulmonary hypertension: Beneficial outcome without reversed pulmonary vascular remodeling

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 5, 2006, Pages 249-254

  Van Albada, Mirjam E ^a,d   Van Veghel, Richard ^c   Cromme Dijkhuis, Adri H ^c   Schoemaker, Regien G ^b   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

Monocrotaline; Prostacyclin; Pulmonary hypertension; Pulmonary vascular histopathology; Surgical arteriovenous shunt

Indexed keywords

MONOCROTALINE; SODIUM CHLORIDE; UNIPROST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTOCAVAL FISTULA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DYSPNEA; HEART FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LOG RANK TEST; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; EPOPROSTENOL; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 33751194658     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000248229.87510.9b     Document Type: Article

References (31)

1. Wagenvoort CA. Lung-Biopsy Specimens in the Evaluation of Pulmonary Vascular-Disease. Chest. 1980;77:614-625.
2. Wagenvoort CA, Mooi WJ. Plexogenic arteriopathy. In: Munro Neville A, Walker F, Gottlieb LS, eds. Biopsy Pathology of the Pulmonary Vasculature. London: Chapman and Hall Medical; 1989:56-113.
3. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43:25S-32S.
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
5. Geiger R, Berger RM, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol. 2000;191:202-207.
6. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-415.
7. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
8. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491.
9. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046-1047.
10. Wade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol. 2004;44:503-509.
11. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44:209-214.
12. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-804.
13. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002;26:194-201.
14. van Albada ME, Schoemaker RG, Kemna M, et al. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J. 2005;26:487-493.
15. Tanaka Y, Schuster DP, Davis EC, et al. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J Clin Invest. 1996;98:434-442.
16. Okada K, Tanaka Y, Bernstein M, et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol. 1997;151:1019-1025.
17. Jones JE, Mendes L, Rudd MA, et al. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol. 2002;283:H364-H371.
18. Kato Y, Iwase M, Kanazawa H, et al. Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats. Exp Anim. 2003;52:285-294.
19. Rabinovitch M, Gamble W, Nadas AS, et al. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol. 1979;236:H818-H827.
20. Wilson DW, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22:307-325.
21. Steffen RP, de la Mata M. The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]. Prostaglandins Leukot Essent Fatty Acids. 1991;43:277-286.
22. Turcato S, Clapp LH. Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. Br J Pharmacol. 1999;126:845-847.
23. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273-277.
24. Tuder RM, Zaiman AL. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? Am J Respir Cell Mol Biol. 2002;26:171-174.
25. Li RC, Cindrova-Davies T, Skepper JN, et al. Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ Res. 2004;94:759-767.
26. Schermuly RT, Yilmaz H, Ghofrani HA, et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:358-363.
27. Ali FY, Egan K, Fitzgerald GA, et al. Role of Prostacyclin Receptor Versus PPAR{beta} with Treprostinil Sodium on Lung Fibroblast Proliferation. Am J Respir Cell Mol Biol. 2006;34:242-246.
28. Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol. 2001;88:1060-1063.
29. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1184-1187.
30. Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med. 2002;165:338-340.
31. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension. Am J Respir Crit Care Med. 2005;172:1586-1589.